These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 15576204)

  • 1. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
    Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
    Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein.
    Carlsson F; Berggård K; Stålhammar-Carlemalm M; Lindahl G
    J Exp Med; 2003 Oct; 198(7):1057-68. PubMed ID: 14517274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway.
    Carlsson F; Sandin C; Lindahl G
    Mol Microbiol; 2005 Apr; 56(1):28-39. PubMed ID: 15773976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system.
    Thern A; Stenberg L; Dahlbäck B; Lindahl G
    J Immunol; 1995 Jan; 154(1):375-86. PubMed ID: 7995956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between complement regulators and Streptococcus pyogenes: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involves two different cell surface molecules.
    Pérez-Caballero D; García-Laorden I; Cortés G; Wessels MR; de Córdoba SR; Albertí S
    J Immunol; 2004 Dec; 173(11):6899-904. PubMed ID: 15557185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR; Dramaix M; Van Melderen L
    Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
    Sandin C; Carlsson F; Lindahl G
    Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor.
    Johnsson E; Berggård K; Kotarsky H; Hellwage J; Zipfel PF; Sjöbring U; Lindahl G
    J Immunol; 1998 Nov; 161(9):4894-901. PubMed ID: 9794423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Streptococcus pyogenes--much more than the aetiological agent of scarlet fever].
    Stock I
    Med Monatsschr Pharm; 2009 Nov; 32(11):408-16; quiz 417-8. PubMed ID: 19947304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 17. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development.
    McArthur JD; Walker MJ
    Mol Microbiol; 2006 Jan; 59(1):1-4. PubMed ID: 16359313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
    Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
    Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.